These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 34196945

  • 1. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
    Lähteenvuo M, Tiihonen J.
    Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
    [Abstract] [Full Text] [Related]

  • 2. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
    Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A.
    JAMA Psychiatry; 2019 May 01; 76(5):499-507. PubMed ID: 30785608
    [Abstract] [Full Text] [Related]

  • 3. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ, Andel R, McPherson M, Tandon R.
    Schizophr Res; 2015 Aug 01; 166(1-3):194-200. PubMed ID: 26141142
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.
    Encephale; 2004 Aug 01; 30(5):417-24. PubMed ID: 15627046
    [Abstract] [Full Text] [Related]

  • 9. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.
    Eur Neuropsychopharmacol; 2009 Jul 01; 19(7):520-32. PubMed ID: 19411165
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Using antipsychotic agents in older patients.
    Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.
    J Clin Psychiatry; 2004 Jul 01; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [Abstract] [Full Text] [Related]

  • 13. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP.
    J Psychopharmacol; 2021 Sep 01; 35(9):1030-1036. PubMed ID: 34256637
    [Abstract] [Full Text] [Related]

  • 14. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
    Fleischhacker WW, Uchida H.
    Int J Neuropsychopharmacol; 2014 Jul 01; 17(7):1083-93. PubMed ID: 22717078
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.
    J Clin Psychiatry; 2004 Oct 01; 65(10):1377-88. PubMed ID: 15491242
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L, Czobor P, Bitter I.
    Schizophr Res; 2014 Jan 01; 152(1):246-54. PubMed ID: 24275583
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.